Loading...
01/09 22:04
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights several risks, including regulatory challenges, financial constraints, and competition. The company reported a net loss, though reduced compared to the previous year, and has limited cash reserves. The Q&A section reveals a lack of detailed guidance and an emphasis on securing additional capital, indicating financial strain. Despite some positive clinical updates, the overall sentiment leans negative due to financial and strategic uncertainties.
Net Loss (Q3 2025) $7.7 million or $0.49 per share, compared to $10.1 million or $1.70 per share in Q3 2024. This represents a decrease in net loss, attributed to reduced research and development expenses and general administrative costs.
Net Loss (9 months ended September 30, 2025) $26.9 million or $2.19 per share, compared to $33.8 million or $5.77 per share for the same period in 2024. The decrease is due to lower research and development and general administrative expenses.
Research and Development Expenses (Q3 2025) $6.4 million, compared to $9.7 million in Q3 2024. The decrease is primarily due to lower employee-related clinical consulting, research, manufacturing, and facility costs.
Research and Development Expenses (9 months ended September 30, 2025) $22.4 million, compared to $29.6 million for the same period in 2024. The reduction is attributed to lower employee-related clinical consulting, research, manufacturing, and facility costs.
General and Administrative Expenses (Q3 2025) $3.7 million, compared to $3.8 million in Q3 2024. The slight decrease is due to lower employee-related costs.
General and Administrative Expenses (9 months ended September 30, 2025) $11.2 million, compared to $13.4 million for the same period in 2024. The decrease is primarily due to lower employee-related costs.
Cash and Cash Equivalents (as of September 30, 2025) $9.1 million. This figure reflects the company's financial position at the end of the reporting period.
TakeAim Lymphoma study: Progressing with emavusertib in combination with ibrutinib for primary CNS lymphoma. Expecting accelerated submissions in the U.S. and Europe within 12-18 months.
CLL proof-of-concept study: Initiating a study to test emavusertib with BTKi monotherapy for deeper responses and reduced resistance. First patient enrollment expected late Q4 2025 or early Q1 2026.
AML triplet study: Evaluating emavusertib with azacitidine and venetoclax in AML patients. Initial data shows MRD conversion in 4 of 8 evaluable patients. Exploring dosing regimens.
Market expansion in CLL and NHL: Engaging with KOLs to expand emavusertib studies into additional NHL subtypes and CLL, aiming to improve treatment paradigms.
Financial performance: Net loss reduced to $7.7M in Q3 2025 from $10.1M in Q3 2024. Cash reserves of $9.1M expected to fund operations into 2026.
R&D and G&A expenses: R&D expenses decreased to $6.4M in Q3 2025 from $9.7M in Q3 2024. G&A expenses slightly decreased to $3.7M in Q3 2025 from $3.8M in Q3 2024.
Strategic focus on emavusertib: Prioritizing emavusertib development across multiple studies to address unmet needs in CNS lymphoma, CLL, and AML.
Regulatory Approval Challenges: The company is awaiting FDA and EMA approval for its TakeAim Lymphoma study and proof-of-concept study in CLL. Delays or rejections could impact strategic timelines and market entry.
Clinical Trial Risks: The success of ongoing trials, including the TakeAim Lymphoma study and AML triplet study, is critical. Any failure to achieve desired outcomes or manage dose-limiting toxicities could hinder progress.
Financial Constraints: The company reported a net loss of $7.7 million for Q3 2025 and has $9.1 million in cash reserves, which may only fund operations into 2026, raising concerns about long-term financial sustainability.
Market Competition: BTK inhibitors are the current standard of care in CLL and NHL. Competing against established treatments and gaining market share could be challenging.
Patient Recruitment Challenges: The company needs to enroll additional patients for its studies to support regulatory submissions, which could face delays or difficulties.
Toxicity and Safety Concerns: Dose-limiting toxicities, such as CPK increase and neutropenia, were observed in the AML triplet study, which could impact patient safety and trial outcomes.
TakeAim Lymphoma Study: The study is evaluating emavusertib in combination with ibrutinib in patients with primary CNS lymphoma. Over the next 12 to 18 months, the company will focus on enrolling additional patients to support accelerated submissions in the U.S. and Europe.
Expansion into Additional NHL Subtypes: Plans to expand emavusertib studies into additional NHL subtypes, particularly for CLL patients, aiming to improve the standard of care by achieving deeper responses and potentially reducing the risk of BTKi resistant mutations.
Proof-of-Concept Study in CLL: A new study protocol has been submitted to the FDA to test emavusertib in CLL patients currently on BTKi monotherapy. The first patient enrollment is expected in late Q4 2025 or early Q1 2026, with initial data anticipated at the ASH Annual Meeting in December 2026.
AML Triplet Study: The ongoing study evaluates the combination of emavusertib with azacitidine and venetoclax in AML patients. Initial data shows promising MRD conversion rates, and further exploration of dosing regimens is planned.
The selected topic was not discussed during the call.
The earnings call highlights several risks, including regulatory challenges, financial constraints, and competition. The company reported a net loss, though reduced compared to the previous year, and has limited cash reserves. The Q&A section reveals a lack of detailed guidance and an emphasis on securing additional capital, indicating financial strain. Despite some positive clinical updates, the overall sentiment leans negative due to financial and strategic uncertainties.
The earnings call presents a mixed picture: while there are positive elements such as decreased expenses and a cash runway into 2026, the net losses and lack of specific guidance in certain areas temper enthusiasm. The Q&A section reveals confidence in ongoing studies but lacks clarity in some responses. The absence of a market cap limits the assessment of stock reaction sensitivity. Given these factors, the overall sentiment remains neutral, with no strong catalysts to drive significant short-term stock movement.
The earnings call highlights several concerns: ongoing financial losses, limited cash reserves, and competitive pressures. Despite some positive developments in clinical trials, there are significant regulatory and clinical risks. The lack of a share repurchase program and vague management responses in the Q&A further contribute to uncertainty. These factors suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
